Updated on 2025/03/26

写真a

 
SUZUKI Yuji
 
Organization
Graduate School of Medicine Center for Research of Laboratory Animals and Medical Research Engineering Division for Advanced Medical Research Assistant Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Assistant Professor
External link

Degree 2

  1. 博士(医学) ( 2024.12   名古屋大学 ) 

  2. 学士(医学) ( 2018.3   順天堂大学 ) 

Awards 1

  1. 若手優秀発表賞

    2023.10   日本生化学会  

 

Papers 8

  1. Systemic administrations of protamine heal subacute spinal cord injury in mice Reviewed Open Access

    Ozaki, T; Sugie, T; Suzuki, Y; Uchimura, K; Suzui, M; Sakamoto, K; Shirane, M; Kadomatsu, K

    NEUROSCIENCE RESEARCH   Vol. 212   page: 11 - 19   2025.3

     More details

    Language:English   Publisher:Neuroscience Research  

    Spinal cord injury (SCI) results in damage to neural circuits that cause long-term locomotor and sensory disability. The objective of the present study is to evaluate whether a clinical drug, protamine, can be employed as a therapeutic agent for SCI. First, we examined the rescue effect of protamine on dystrophic endballs (DEs) cultured on a chondroitin sulfate (CS) gradient coating. Consequently, axons with DE, which are unable to grow through the CS barrier, resumed growth after protamine treatment and were able to pass through the barrier. In addition, we tested whether protamine resolves the DE phenotype, accumulation of autophagosomes. The results demonstrated that protamine has significantly reduced the density of LC3 in DEs. Subsequently, mice were administered 1 mg/kg protamine via the tail vein one week following a contusion injury to the thoracic spinal cord. The hindlimb movements of the mice were evaluated in order to assess the therapeutic effect of protamine. Eleven venous administrations of protamine improved the symptoms. The current study has demonstrated that protamine cancels the CS inhibitory effect on axonal regrowth. Administrations of protamine were observed to alleviate hindlimb motor dysfunction in SCI mice. Our results suggest an effective therapeutic agent for SCI and a possibility for drug repositioning. It would be of interest to see if protamine also exerts a therapeutic effect in brain injury.

    DOI: 10.1016/j.neures.2024.12.001

    Open Access

    Web of Science

    Scopus

    PubMed

  2. Identification of APBB1 as a substrate for anaplastic lymphoma kinase Reviewed

    Suzuki, Y; Tsubota, S; Kadomatsu, K; Sakamoto, K

    JOURNAL OF BIOCHEMISTRY     2024.8

     More details

  3. Glypican-2 as the Regeneration-Associated Gene (RAG) Invited Reviewed

    Journal of Experimental Neurology     2023.8

     More details

    Language:English  

  4. Glypican-2 defines age-dependent axonal response to chondroitin sulfate Reviewed

    Experimental Neurology     2023.5

     More details

    Language:English  

  5. Towards the in vivo identification of protein–protein interactions Invited Reviewed

    Journal of biochemistry     2023.2

     More details

    Authorship:Lead author   Language:English  

  6. Close association of polarization and LC3, a marker of autophagy, in axon determination in mouse hippocampal neurons Reviewed

    Experimental Neurology     2022.5

     More details

    Language:English  

  7. Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase Reviewed

    Journal of biochemistry     2021.7

     More details

    Language:English  

  8. Type IIa RPTPs and Glycans: Roles in Axon Regeneration and Synaptogenesis Invited Reviewed

    International Journal of Molecular Sciences     2021.5

     More details

    Language:English  

▼display all

Books 1

  1. 最先端ナノライフシステム研究

    ( Role: Contributor)

    2022.3 

     More details

    Language:Japanese